Conflict of interest
G. Baretton received consultant fees from AstraZeneca GmbH, Bristol-Myers Squibb GmbH & Co. KGaA, MSD Sharp & Dohme GmbH, and Roche Deutschland Holding GbmH; received other fees from Astellas Pharma GmbH, AstraZeneca GmbH and Daiichi Sankyo Deutschland GmbH for presentations and lectures; was reimbursed for travel expenses by MSD Sharp & Dohme GmbH; is Chairman of the DGP Deutsche Gesellschaft für Pathologie e.V.. T. Gaiser received fees from Bristol-Myers Squibb GmbH & Co. KGaA, MSD Sharp & Dohme GmbH and Roche Deutschland Holding GbmH for consulting activities and lectures. R. Hofheinz received consultant fees from Amgen GmbH, AstraZeneca GmbH, Bayer AG, Boehringer Ingelheim Pharma GmbH & Co. KG, Bristol-Myers Squibb GmbH & Co. KGaA, Daiichi Sankyo Deutschland GmbH, Leo Pharma GmbH, Lilly Deutschland GmbH, medac GmbH, Merck KGaA, MSD Sharp & Dohme GmbH, Nordic Pharma GmbH, Pierre Fabre S.A., Roche Deutschland Holding GbmH, Saladax Biomedical, Sanofi-Aventis Deutschland GmbH, Servier Deutschland GmbH and Synlab Holding Deutschland GmbH; received other fees from Amgen GmbH, AstraZeneca GmbH, Bayer AG, Boehringer Ingelheim Pharma GmbH & Co. KG, Bristol-Myers Squibb GmbH & Co. KGaA, Daiichi Sankyo Deutschland GmbH, Leo Pharma GmbH, Lilly Deutschland GmbH, medac GmbH, Merck KGaA, MSD Sharp & Dohme GmbH, Nordic Pharma GmbH, Pierre Fabre S. A., Roche Deutschland Holding GbmH, Saladax Biomedical, Sanofi-Aventis Deutschland GmbH, Servier Deutschland GmbH, Synlab Holding Deutschland GmbH and was active as an appraiser for Deutsche Krebshilfe. D. Horst has received fees from Bristol-Myers Squibb GmbH & Co. KGaA for speaking engagements. F. Lordick received fees for lectures, expert appraisal or consulting services from Amgen GmbH, Astellas Pharma GmbH, AstraZeneca GmbH, Bayer AG, BioNTech SE, Bristol-Myers Squibb GmbH & Co. KGaA, Daiichi Sankyo Deutschland GmbH, Lilly Deutschland GmbH, Elsevier GmbH, Falk Foundation e.V., Incyte Inc, Merck KGaA, MSD Sharp & Dohme GmbH, Novartis Pharma GmbH, Roche Deutschland Holding GbmH, Servier Deutschland GmbH, Springe Nature AG & Co. KGaA, StreamedUp! GmbH; research projects are supported by Bristol-Myers Squibb GmbH und Co. KGaA and Gilead Science GmbH. S. Lorenzen received consultant fees from Amgen GmbH, AstraZeneca GmbH, Bayer AG, Boehringer Ingelheim Pharma GmbH & Co. KG, Bristol-Myers Squibb GmbH & Co. KGaA, Daiichi Sankyo Deutschland GmbH, Leo Pharma GmbH, Lilly Deutschland GmbH, medac GmbH, Merck KGaA, MSD Sharp & Dohme GmbH, Nordic Pharma GmbH, Pierre Fabre S. A., Roche Deutschland Holding GbmH, Saladax Biomedical, Sanofi-Aventis Deutschland GmbH, Servier Deutschland GmbH, Synlab Holding Deutschland GmbH; other fees from Amgen GmbH, AstraZeneca GmbH, Bayer AG, Bristol-Myers Squibb GmbH & Co. KGaA, Boehringer Ingelheim Pharma GmbH & Co. KG, Daiichi Sankyo Deutschland GmbH, Leo Pharma GmbH, Lilly Deutschland GmbH, medac GmbH, Merck KGaA, MSD Sharp & Dohme GmbH, Nordic Pharma GmbH, Pierre Fabre S. A., Roche Deutschland Holding GbmH, Saladax Biomedical, Sanofi- Aventis Deutschland GmbH, Servier Deutschland GmbH and Synlab Holding Deutschland GmbH; research projects are supported by Bristol-Myers Squibb GmbH & Co. KGaA and Lilly Deutschland GmbH (study partial funding); received non-financial support from AIO-Studien-GmbH, Amgen GbmH, Bristol-Myers Squibb GmbH & Co. KGaA, BMBF, Deutsche Krebshilfe, European Organization for Research and Treatment of Cancer; declared to have an advisory role and to receive research grants from Bristol-Myers Squibb GmbH & Co. KGaA. M. Moehler is Head of the Gastroenterological Oncology Outpatient Clinic at Mainz University Hospital; received consultant fees from Amgen GmbH, AstraZeneca GmbH, Bristol-Myers Squibb GmbH & Co. KGaA, Lilly Deutschland GmbH, Merck KGaA, MSD Sharp & Dohme GbmH, Onyx Pharma Ltd, Pfizer Deutschland GmbH, Roche Deutschland Holding GbmH, Taiho Pharmaceutical Co, Ltd, as well as other fees from Amgen GmbH, ASCO, AstraZeneca GmbH, Bristol-Myers Squibb GmbH & Co. KGaA, Dr. Falk Pharma GmbH, ESMO, Lilly Deutschland GmbH, mci, MSD Sharp & Dohme GmbH, Merck KGaA, Nordic Pharma GmbH, Pfizer Deutschland GmbH; receives funding for scientific research from AIO-Studien-GmbH, Amgen GmbH, EORTC, Merck KGaA, MSD Sharp & Dohme GmbH, AIO-Studien-GmbH, Taiho Pharmaceutical Co, Ltd. C. Röcken is a member of the advisory boards and receives honoraria for lectures from Alnylam Pharmaceutical, Inc, Astellas Pharma GmbH, Bristol-Myers Squibb GmbH & Co. KGaA, Janssen-Cilag GmbH, MSD Sharp & Dohme GmbH and Pfizer. P. Schirmacher received fees from Bristol-Myers Squibb GmbH & Co. KGaA, Chugai Pharmaceutical Co., Ltd, Gilead Science GmbH, Incyte Inc, PathAI Inc; is a member of the advisory boards from Bristol-Myers Squibb GmbH & Co. KGaA, Eisai GmbH, Incyte Inc., Leica, MSD Sharp & Dohme GbmH; received fees as Speaker for Bristol-Myers Squibb GmbH & Co. KGaA, Incyte Inc., Jannsen-Cilag GmbH and Leica. M. Stahl is a member of the advisory boards from Amgen GmbH, Bristol-Myers Squibb GmbH & Co. KGaA, Daiichi Sankyo Deutschland GmbH, Lilly Deutschland GmbH, MSD Sharp & Dohme GmbH, Novartis Pharma GmbH, Pfizer Deutschland GmbH and Servier Deutschland GmbH; received fees for lectures from Amgen GmbH, Bristol-Myers Squibb GmbH & Co. KGaA, Lilly Deutschland GmbH, Merck KGaA and Roche Deutschland Holding GbmH. P. Thuss-Patience is a member of the advisory boards of Astellas Pharma GmbH, AstraZeneca GmbH, Bristol-Myers Squibb GmbH & Co. KGaA, Daiichi Sankyo Deutschland GmbH, Lilly Deutschland GmbH, Merck KGaA, MSD Sharp & Dohme GmbH, Roche Deutschland Holding GbmH, Novartis Pharma GmbH; received support for travel expenses from Merck KGaA. K. Tiemann received fees as a member of the advisory boards and for lectures from AstraZeneca GmbH, Bristol-Myers Squibb GmbH & Co. KGaA, MSD Sharp & Dohme GmbH and Roche Deutschland Holding GbmH.